Pancrelipase in combination with Ensure Plus
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency
Conditions
Exocrine Pancreatic Insufficiency, Pancreatitis, Chronic, Steatorrhea, Pancreatitis
Trial Timeline
Jul 1, 2008 → Jan 1, 2009
NCT ID
NCT00676702About Pancrelipase in combination with Ensure Plus
Pancrelipase in combination with Ensure Plus is a phase 1 stage product being developed by Johnson & Johnson for Exocrine Pancreatic Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00676702. Target conditions include Exocrine Pancreatic Insufficiency, Pancreatitis, Chronic, Steatorrhea.
What happened to similar drugs?
3 of 4 similar drugs in Exocrine Pancreatic Insufficiency were approved
Approved (3) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00676702 | Phase 1 | Completed |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 40 |
| CREON | AbbVie | Approved | 35 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 35 |
| Pancrelipase + Placebo | AbbVie | Approved | 35 |
| Pancrelipase Capsules | AbbVie | Approved | 50 |
| Lipacreon | Viatris | Pre-clinical | 23 |